The TAPS Trial - Fetoscopic Laser Surgery for Twin Anemia Polycythemia Sequence
- Conditions
- Twin Anemia Polycythemia Sequence
- Interventions
- Procedure: Fetoscopic Laser SurgeryOther: Standard Treatment
- Registration Number
- NCT04432168
- Lead Sponsor
- Leiden University Medical Center
- Brief Summary
This multicenter open-label randomized controlled trial is set up to evaluate the effect of fetoscopic laser surgery on the gestational age at birth for monochorionic twin pregnancies diagnosed with twin anemia-polycythemia sequence. Half op the patients will be treated with fetoscopic laser surgery, while the other half will be managed with standard treatment. The hypothesis is that fetoscopic laser therapy will improve neonatal outcome by prolonging pregnancy.
- Detailed Description
Rationale: Monochorionic twins share one placenta and are connected to each other via vascular anastomoses at the placental surface, allowing the blood to transfer bi-directionally between the two fetuses. Unbalanced inter-twin blood transfusion can result in twin anemia-polycythemia sequence (TAPS). Management options include: fetoscopic laser surgery, intrauterine blood transfusion (IUT) with or without partial exchange transfusion (PET), preterm delivery, selective feticide and expectant management. The optimal treatment for TAPS is not clear. Fetoscopic laser surgery is the only causative treatment option, but data on the feasibility of this procedure are mainly based on case reports and small cohort studies. A large randomized controlled trial is needed to evaluate the possible beneficial effect of fetoscopic laser surgery and to determine the optimal treatment option for TAPS.
Objective: The aim of this trial is to investigate whether fetoscopic laser surgery improves the outcome for TAPS twins as compared to the control group (standard care consisting of expectant management, IUT, preterm delivery). The hypothesis is that fetoscopic laser therapy will improve neonatal outcome by prolonging pregnancy.
Study design: International multi-centered open-label randomized controlled trial to assess whether fetoscopic laser surgery (experimental group) improves the outcome of TAPS twins compared to standard care (control group).
Study population: Monochorionic twin pregnancies with TAPS stage ≥ 2 (spontaneous or post-laser) diagnosed between 20 and 28 weeks of gestation.
Intervention: In the experimental group fetoscopic laser surgery is performed, whereas the control group is treated with standard care (expectant management, IUT (with PET), selective feticide and/or preterm delivery, depending on the opinion of the fetal surgeon).
Main study endpoints: The primary outcome is gestational age at birth. Secondary outcomes include: perinatal mortality or severe neonatal morbidity, hematological complication, procedure related complications and long-term neurodevelopmental outcome at 2 years.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- Female
- Target Recruitment
- 44
- Monochorionic twin pregnancy complicated by either spontaneous or post-laser twin anemia polycythemia sequence (TAPS), stage ≥ 2, diagnosed between 20+0 and till 28+0 weeks of gestation
- Women aged 18 years or more, who are able to consent.
- Written informed consent to participate in this randomized controlled trial, forms being approved by the Ethical Committees.
- TAPS stage 1
- TAPS stage≥ 2, diagnosed within 1 week after laser surgery for twin-twin transfusion syndrome (TTTS) (a large inter-twin middle cerebral artery peak systolic velocity difference within a week after laser for TTTS is likely to related to hemodynamic reequilibration, and is usually not based on TAPS)
- Triplet pregnancies, or higher order multiple pregnancies
- TAPS cases that already underwent an intrauterine treatment (with the exception of laser surgery for TTTS in post-laser TAPS cases)
- Congenital abnormalities (including severe cerebral injury) in one or both twins
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Fetoscopic Laser Surgery Fetoscopic Laser Surgery fetoscopic laser coagulation of the vascular anastomoses at the placental surface Standard Treatment Standard Treatment Expectant management, IUT (with or without PET), preterm delivery
- Primary Outcome Measures
Name Time Method Gestational Age at Birth 2 weeks after expected date of birth Gestational age: completed weeks + additional days since the first day of the last menstruational period of the mother.
- Secondary Outcome Measures
Name Time Method Number of patients with severe neonatal morbidity 42 days (28 days neonatal period+2 weeks postdates) after expected date of birth Severe neonatal morbidity is defined as the presence of at least one of the following:
* Respiratory distress syndrome requiring surfactant or mechanical ventilation
* Proven early onset neonatal sepsis with positive blood cultures within 72 hours postpartum
* Retinopathy of prematurity stage 3 or higher
* Necrotizing enterocolitis stage 2 or higher
* Patent ductus arteriosus requiring medical therapy or surgical closure
* Severe cerebral injury (defined as intraventricular hemorrhage grade 3 or higher, cystic periventricular leukomalacia grade 2 or higher, ventricular dilatation greater than the 97th centile, porencephalic or parenchymal cysts or other severe cerebral lesions)Number of patients with hematological complications 2 weeks after expected date of birth Hematological complications are defined as the presence of at least one of the following:
* Anemia in donor requiring a blood transfusion within 24 hours after birth
* Polycythemia in recipient requiring a partial exchange transfusion within 24 hours after birth
* necrotic skin injury
* limb ischemia
* platelet count \< 150,000/microL
* albumin levels \< 20 g/L
* protein levels \< 40 g/LNumber of patients with procedure-related complications 2 weeks after expected date of birth Procedure-related complications are defined as at least one of the following:
* amniotic band syndrome
* iatrogenic monoamnionicity
* Preterm premature rupture of the membranes
* Placental abruption
* clinical chorioamnionitis
* histological chorioamnionitis and/or funisitisNumber of patients with behavioral problems 2 years after expected date of birth Behavioral problems are defined as a T-score ≥ 64 for one of the following broad band scales: total problem score, Internalizing problems (anxious/depressed, withdrawn, somatic complaints), Externalizing problems (rule-breaking, aggressive behavior) as measured with the Child Behaviour Checklist 1.5-5 years
Number of patients with perinatal mortality 42 days (28 days neonatal period+2 weeks postdates) after expected date of birth Perinatal mortality is defined as fetal death or neonatal death (demise of a liveborn child within 28 days after birth)
Number of patient with mild neurodevelopmental impairment 2 years after expected date of birth Mild neurodevelopmental impairment is defined as at least one of the following:
* cerebral palsy (spastic bilateral, spastic unilateral, or mixed)
* Impaired cognitive or motor development defined as Score \< 85 (1 standard deviation (SD) below the mean) as assessed by Bayley Scales of Infant and Toddler Development version 3 (BSID-III)
* Impaired functioning in communication, fine and gross motor, problem solving, personal and social functioning defined as Score \> 1 SD below the mean as assessed by Ages and Stages Questionnaire version 3 (ASQ-III)
* severe visual loss (blind or partially sighted)
* severe hearing loss (needing hearing aids)Number of patients with severe neurodevelopmental impairment 2 years after expected date of birth Severe neurodevelopmental impairment is defined as at least one of the following:
* cerebral palsy defined as a gross motor function classification system (CMFCS) grade \> 1
* Impaired cognitive or motor development defined as a score \< 70 (2 SD below the mean) as assessed by the Bayley Scales of Infant and Toddler Development version 3 (BSID-III)
* Impaired functioning in communication, fine and gross motor, problem solving, personal and social functioning defined as a score \> 2 SD below the mean as assessed by Ages and Stages Questionnaire version 3 (ASQ-III)
* Bilateral blindness defined as visual acuity of less than 3/60 in the better eye
* Bilateral deafness defined as severe or profound hearing loss in both ears (severe hearing loss: a person can only hear sounds \> 70-89 decibel , profound hearing loss: a person can only hear sounds \> 90 decibel
Trial Locations
- Locations (5)
Leiden University Medical Center
🇳🇱Leiden, South-Holland, Netherlands
Vittore Buzzi Children's Hospital
🇮🇹Milan, Lombardy, Italy
Karolinska University Hospital
🇸🇪Stockholm, Södermanland, Sweden
Vall d'Hebron University Hospital
🇪🇸Barcelona, Spain
Yale University
🇺🇸New Haven, Connecticut, United States